In summary, this investigation provides an in-depth reference map of the KRasG12V surface that may facilitate more rapid selection and further validation of candidate targets for the generation of therapeutic antibodies against surface proteins in the context of immune therapy for KRas-driven cancers. The gene discussed is KRAS; the disease is cancer.